NeuroSearch drug trial results cheer stock market  

NeuroSearch's share price jumps 8% on positive final results of a metabolic study of obesity & type 2 diabetes drug candidate tesofensine
Danish biopharmaceutical company NeuroSearch has announced in a press release the final results of a human metabolic study of its obesity and type 2 diabetes drug candidate tesofensine. The study supports tesofensine's potential as an effective new treatment for these conditions, and shows that weight reduction is obtained through both appetite suppression and a favourable impact on energy and fat metabolism.
The OMX Nordic Exchange Copenhagen responded warmly to the news on Monday, with NeuroSearch's share price leaping 8.2%.
The study involved 32 overweight and obese subjects being treated for 14 days with either tesofensine or placebo. The study found that tesofensine, which belongs to a category of drugs called monoamine reuptake inhibitors, reduces appetite sensations, reduces fat tissue, improves insulin sensitivity and increases energy expenditure at rest.
NeuroSearch develops novel drugs based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company’s activities are partner financed through a broad alliance with GlaxoSmithKline and collaborations with Abbott and Astellas. The drug pipeline comprises 14 clinical development (Phase I-III) programmes, including a Phase III drug candidate in Huntington's disease.
Link > NeuroSearch   

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×